4//SEC Filing
Suri Anish 4
Accession 0000899243-21-044603
CIK 0001645460other
Filed
Nov 14, 7:00 PM ET
Accepted
Nov 15, 5:00 PM ET
Size
9.3 KB
Accession
0000899243-21-044603
Insider Transaction Report
Form 4
Suri Anish
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2021-11-11$6.42/sh+20,000$128,400→ 114,038 total - Sale
Common Stock
2021-11-11$15.07/sh−20,000$301,354→ 94,038 total - Exercise/Conversion
Stock Option (right to buy)
2021-11-11−20,000→ 105,000 totalExercise: $6.42Exp: 2029-03-06→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.29, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The option vests in eight equal semi-annual installments beginning September 6, 2019.
Documents
Issuer
Cue Biopharma, Inc.
CIK 0001645460
Entity typeother
Related Parties
1- filerCIK 0001739130
Filing Metadata
- Form type
- 4
- Filed
- Nov 14, 7:00 PM ET
- Accepted
- Nov 15, 5:00 PM ET
- Size
- 9.3 KB